|
1
|
Georgakopoulou EA, Achtari MD, Achtaris M,
Foukas PG and Kotsinas A: Oral lichen planus as a preneoplastic
inflammatory model. J Biomed Biotechnol. 2012:7596262012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bombeccari GP, Guzzi G, Tettamanti M,
Gianni AB, Baj A, Pallotti F and Spadari F: Oral lichen planus and
malignant transformation: A longitudinal cohort study. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 112:328–334. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shen ZY, Liu W, Feng JQ, Zhou HW and Zhou
ZT: Squamous cell carcinoma development in previously diagnosed
oral lichen planus: De novo or transformation? Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 112:592–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warnakulasuriya S, Johnson NW and Van der
Waal I: Nomenclature and classification of potentially malignant
disorders of the oral mucosa. J Oral Pathol Med. 36:575–580. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van der Waal I: Potentially malignant
disorders of the oral and oropharyngeal mucosa; terminology,
classification and present concepts of management. Oral Oncol.
45:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Safadi RA, Al Jaber SZ, Hammad HM and
Hamasha AA: Oral lichen planus shows higher expressions of tumor
suppressor gene products of p53 and p21 compared to oral mucositis.
An immunohistochemical study. Arch Oral Biol. 55:454–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Georgakopoulou EA, Troupis TG, Troupis G
and Gorgoulis VG: Update of the cancer-associated molecular
mechanisms in oral lichen planus, a disease with possible
premalignant nature. J BUON. 16:613–616. 2011.PubMed/NCBI
|
|
8
|
Accurso BT, Warner BM, Knobloch TJ,
Weghorst CM, Shumway BS, Allen CM and Kalmar JR: Allelic imbalance
in oral lichen planus and assessment of its classification as a
premalignant condition. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 112:359–366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andrews JL, Kim AC and Hens JR: The role
and function of cadherins in the mammary gland. Breast Cancer Res.
14:2032012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodriguez FJ, LewisTuffin LJ and
Anastasiadis PZ: E-cadherin's dark side: Possible role in tumor
progression. Biochim Biophys Acta. 1826:23–31. 2012.PubMed/NCBI
|
|
11
|
Kang HG, Jenabi JM, Zhang J, Keshelava N,
Shimada H, May WA, Ng T, Reynolds CP, Triche TJ and Sorensen PH:
E-cadherin cell-cell adhesion in Ewing tumor cells mediates
suppression of anoikis through activation of the ErbB4 tyrosine
kinase. Cancer Res. 67:3094–3105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsalikidis C, Papachristou F, Pitiakoudis
M, Asimakopoulos B, Trypsianis G, Bolanaki E, Syrigos KN and
Simopoulos C: Soluble E-cadherin as a diagnostic and prognostic
marker in gastric carcinoma. Folia Med (Plovdiv). 55:26–32.
2013.PubMed/NCBI
|
|
13
|
Wójcik-Krowiranda K, Forma E, Zaczek A,
Bryś M, Anna MK and Bieńkiewicz A: Expression of E-cadherin and
beta1-integrin mRNA in endometrial cancer. Ginekol Pol. 84:910–914.
2013.(In Polish). View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hashiguchi M, Ueno S, Sakoda M, Iino S,
Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et
al: Clinical implication of ZEB-1 and E-cadherin expression in
hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Auvinen E, Carpen O, Korpela T, Ronty M,
Vaheri A and Tarkkanen J: Altered expression of ezrin, E-cadherin
and β-catenin in cervical neoplasia. Neoplasma. 60:56–61. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kyrodimou M, Andreadis D, Drougou A,
Amanatiadou EP, Angelis L, Barbatis C, Epivatianos A and
Vizirianakis IS: Desmoglein-3/γ-catenin and E-cadherin/β-catenin
differential expression in oral leukoplakia and squamous cell
carcinoma. Clin Oral Investig. 18:199–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poomsawat S, Buajeeb W, Khovidhunkit SO
and Punyasingh J: Overexpression of cdk4 and p16 in oral lichen
planus supports the concept of premalignancy. J Oral Pathol Med.
40:294–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Supic G, Kozomara R, Jovic N, Zeljic K and
Magic Z: Prognostic significance of tumor-related genes
hypermethylation detected in cancer-free surgical margins of oral
squamous cell carcinomas. Oral Oncol. 47:702–708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soslow RA, Dannenberg AJ, Rush D, Woerner
BM, Khan KN, Masferrer J and Koki AT: Cox-2 is expressed in human
pulmonary, colonic and mammary tumors. Cancer. 89:2637–2645. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Regezi JA, Sciubba JJ and Jordan RCK: Oral
Pathology: Clinical Pathologic Correlations. 6th. Elsevier
Saunders; St. Louis, MO: 2012
|
|
21
|
Sun L, Feng J, Ma L, Liu W and Zhou Z:
CD133 expression in oral lichen planus correlated with the risk for
progression to oral squamous cell carcinoma. Ann Diagn Pathol.
17:486–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sleeman JP and Thiery JP: SnapShot: The
epithelial-mesenchymal transition. Cell. 145:162.e12011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wells A, Chao YL, Grahovac J, Wu Q and
Lauffenburger DA: Epithelial and mesenchymal phenotypic switchings
modulate cell motility in metastasis. Front Biosci (Landmark Ed).
16:815–837. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kolesnik AP, Shevchenko AI, Tumanskiĭ VA
and Evseev AV: Effect of the intercellular adhesion molecule
E-cadherin on the prognosis of non-small cell lung cancer. Arkh
Patol. 75:30–33. 2013.(In Russian). PubMed/NCBI
|
|
25
|
Horne HN, Sherman ME, GarciaClosas M,
Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J,
Brinton LA, et al: Breast cancer susceptibility risk associations
and heterogeneity by E-cadherin tumor tissue expression. Breast
Cancer Res Treat. 143:181–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sekar P, Bharti JN, Nigam JS, Sharma A and
Soni PB: Evaluation of p53, HoxD10 and E-cadherin status in breast
cancer and correlation with histological grade and other prognostic
factors. J Oncol. 2014:7025272014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deep G, Jain AK, Ramteke A, Ting H,
Vijendra KC, Gangar SC, Agarwal C and Agarwal R: SNAI1 is critical
for the aggressiveness of prostate cancer cells with low
E-cadherin. Mol Cancer. 13:372014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakagawa H, Hikiba Y, Hirata Y,
FontBurgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A,
Kinoshita H, Sakitani K, et al: Loss of liver E-cadherin induces
sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad
Sci USA. 111:1090–1095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
30
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalluri R: EMT: When epithelial cells
decide to become mesenchymal-like cells. J Clin Investig.
119:1417–1419. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
von Zeidler SV, de Souza Botelho T,
Mendonça EF and Batista AC: E-cadherin as a potential biomarker of
malignant transformation in oral leukoplakia: A retrospective
cohort study. BMC Cancer. 14:9722014. View Article : Google Scholar : PubMed/NCBI
|
